Paclitaxel and Erlotinib-co-loaded Solid Lipid Core Nanocapsules: Assessment of Physicochemical Characteristics and Cytotoxicity in Non-small Cell Lung Cancer
- Paclitaxel and Erlotinib-co-loaded Solid Lipid Core Nanocapsules: Assessment of Physicochemical Characteristics and Cytotoxicity in Non-small Cell Lung Cancer
- Erlotinib; paclitaxel; solid lipid core nanocapsules; non-small cell lung cancer; HIGH-DOSE CISPLATIN; COMBINATION CHEMOTHERAPY; PHASE-II; SEQUENTIAL DELIVERY; DRUG-DELIVERY; SINGLE-AGENT; MITOMYCIN-C; NANOPARTICLES; THERAPY; VINORELBINE
- Issue Date
- SPRINGER/PLENUM PUBLISHERS
- PHARMACEUTICAL RESEARCH, v. 35, No. 5, Article no. 96
- Purpose Lung cancer is the leading cause of cancer-related deaths. The aim of this study was to design solid lipid core nanocapsules (SLCN) comprising a solid lipid core and a PEGylated polymeric corona for paclitaxel (PTX) and erlotinib (ERL) co-delivery to non-small cell lung cancer (NSCLC), and evaluate their physicochemical characteristics and in vitro activity in NCI-H23 cells.
Methods PTX/ERL-SLCN were prepared by nanoprecipitation and sonication and physicochemically characterized by dynamic light scattering, transmission electron microscopy, differential scanning calorimetry, X-ray diffraction, and Fourier-transform infrared spectroscopy. In vitro release profiles at pH7.4 and pH5.0 were studied and analyzed. In vitro cytotoxicity and cellular uptake and apoptosis assays were performed in NCI-H23 cells.
Results PTX/ERL-SLCN exhibited appropriately-sized spherical particles with a high payload. Both PTX and ERL showed pH-dependent and sustained release in vitro profiles. PTX/ERL-SLCN demonstrated concentration-and timedependent uptake by NCI-H23 cells and caused dosedependent cytotoxicity in the cells, which was remarkably greater than that of not only the free individual drugs but also the free drug cocktail. Moreover, well-defined early and late apoptosis were observed with clearly visible signs of apoptotic nuclei.
Conclusion PTX/ERL-SLCN could be employed as an optimal approach for combination chemotherapy of NSCLC.
- 1573-904X; 0724-8741
- Appears in Collections:
- COLLEGE OF PHARMACY[E](약학대학) > PHARMACY(약학과) > Articles
- Files in This Item:
There are no files associated with this item.
- RIS (EndNote)
- XLS (Excel)